hoxc13b Antibody

What is HOXC13 and what are its primary functions in cellular biology?

HOXC13 is a homeobox transcription factor that plays essential roles in cellular differentiation and tissue development. It functions primarily as a regulator of gene expression by binding to specific DNA sequences through its homeodomain. HOXC13 is particularly important in hair follicle differentiation, where it regulates FOXQ1 expression and other hair-specific genes . The transcription factor belongs to the larger HOX gene family, which consists of DNA-binding proteins involved in embryonic development and tissue-specific cellular differentiation programs. Understanding HOXC13's function provides important context for antibody-based detection methods in developmental biology and pathology research.

What are the typical applications for HOXC13 antibodies in research settings?

HOXC13 antibodies are primarily utilized in the following research applications:

*Based on comparable HOX antibody applications

These applications enable researchers to investigate HOXC13 expression patterns across different tissues, detect alterations in protein levels under various experimental conditions, and examine its subcellular localization. Unlike commercial inquiries about availability and pricing, this information focuses on the scientific applications relevant to experimental design and data interpretation in academic research.

How does HOXC13 expression differ from other HOX family members like HOXB13?

While both HOXC13 and HOXB13 are homeodomain-containing transcription factors, they exhibit distinct tissue-specific expression patterns and functional roles. HOXB13 is predominantly expressed in prostate tissue and plays a critical role in prostate gland differentiation . High expression levels of HOXB13 are observed during the later stages of prostate development, and it remains expressed in prostate cancer cells . In contrast, HOXC13 demonstrates stronger expression in epithelial tissues, particularly in hair follicles, where it regulates keratinocyte differentiation and hair development .

The molecular weight of HOXC13 differs from HOXB13, with HOXC13 having a higher molecular weight compared to HOXB13's 31-35 kDa range . This distinction is important when selecting appropriate antibodies and interpreting western blot results. Understanding these differences is crucial for researchers designing experiments to investigate tissue-specific developmental programs and pathological conditions.

How can HOXC13 antibodies be optimized for dual immunofluorescence studies with other HOX family proteins?

For dual immunofluorescence studies involving HOXC13 and other HOX proteins, researchers should implement the following optimization strategies:

• Antibody Species Selection: Choose primary antibodies raised in different host species (e.g., rabbit anti-HOXC13 and mouse anti-HOXB13) to prevent cross-reactivity during secondary antibody detection .

• Sequential Staining Protocol: For antibodies from the same host species, employ sequential staining with a complete blocking step between antibody applications:

  • Apply first primary antibody at 1:100 dilution

  • Detect with fluorophore-conjugated secondary antibody

  • Block with excess unconjugated host-specific F(ab) fragments

  • Apply second primary antibody

  • Detect with differently colored fluorophore-conjugated secondary antibody

• Validation Controls: Always include single-antibody controls on separate tissue sections to confirm specificity and absence of bleed-through between fluorescence channels.

• Antibody Dilution Optimization: Perform dilution series experiments (1:50, 1:100, 1:200, 1:500) with both antibodies to identify optimal signal-to-noise ratios for each target protein .

This methodological approach enables researchers to accurately study the co-expression patterns of multiple HOX family proteins within the same tissue sections, providing insights into their functional relationships during development and in pathological states.

What are the critical considerations when using HOXC13 antibodies for chromatin immunoprecipitation (ChIP) experiments?

When implementing ChIP experiments with HOXC13 antibodies, researchers should consider several critical factors to ensure experimental success:

• Antibody Validation: Confirm the antibody's specificity and efficiency for immunoprecipitation applications through preliminary testing:

  • Western blot to verify single-band specificity

  • Immunoprecipitation followed by Western blot detection

  • Use positive controls (tissues/cells with known HOXC13 expression) and negative controls (tissues/cells without HOXC13 expression)

• Crosslinking Optimization: Given HOXC13's function as a transcription factor:

  • Test formaldehyde concentrations between 0.5-1.5%

  • Optimize crosslinking time (typically 10-15 minutes)

  • Consider dual crosslinking with formaldehyde and disuccinimidyl glutarate for enhanced protein-DNA complexes

• Chromatin Fragmentation: For transcription factors like HOXC13:

  • Aim for DNA fragments of 200-500 bp

  • Optimize sonication parameters for consistent fragmentation

  • Verify fragment size by agarose gel electrophoresis

• Antibody Concentration: Use higher antibody concentrations (2-5 μg per ChIP reaction) than typically used for western blot applications to ensure efficient immunoprecipitation of protein-DNA complexes.

These methodological considerations address the unique challenges of using antibodies for chromatin immunoprecipitation, focusing on the specific properties of transcription factors like HOXC13 rather than general commercial aspects of antibody products.

How does methylation status affect HOXC13 detection by antibodies compared to other HOX family members?

DNA methylation can significantly impact the detection of HOX family proteins by antibodies through several mechanisms. Research on HOXB13 demonstrates that gene body CpG methylation is associated with reduced expression in neuroendocrine prostate cancers (NEPCs) . This finding suggests that similar epigenetic mechanisms may affect HOXC13 expression and detection.

Key considerations regarding methylation effects on HOXC13 antibody detection include:

• Epigenetic Regulation: Methylation of the HOXC13 promoter region may reduce gene expression, resulting in lower protein levels for antibody detection. In comparative studies, researchers should evaluate methylation status when interpreting antibody signal intensity.

• Conformational Changes: Methylation-associated chromatin remodeling may alter nuclear organization and accessibility of epitopes, potentially affecting antibody binding efficiency in fixed tissue samples.

• Methodological Adjustments:

  • For tissues with suspected high methylation, extended antigen retrieval protocols may improve detection

  • In methylation-dense regions, chromatin accessibility agents may enhance antibody penetration

  • Parallel analysis of methylation status and protein expression provides more comprehensive interpretation

• Comparative Analysis: Based on findings from HOXB13 research , a combined approach that correlates DNA methylation analysis with antibody-based protein detection would provide more comprehensive insights into HOX protein expression patterns in development and disease.

This advanced research question addresses the complex interplay between epigenetic modifications and protein detection methodologies, providing guidance for researchers investigating HOX protein expression in contexts where epigenetic alterations are relevant.

What are the optimal fixation and antigen retrieval protocols for HOXC13 immunohistochemistry?

Optimal fixation and antigen retrieval protocols are critical for successful HOXC13 immunohistochemistry. Based on comparable protocols for HOX family proteins, the following methodological approach is recommended:

• Tissue Fixation:

  • Fix tissues in 10% neutral-buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Section tissues at 4-5 μm thickness

• Antigen Retrieval Methods:

  • Heat-Induced Epitope Retrieval (HIER):

    • Primary method: Tris-EDTA buffer (pH 9.0) at 95-98°C for 20 minutes

    • Alternative method: Citrate buffer (pH 6.0) for 20 minutes at 95-98°C

  • Allow slides to cool in the retrieval solution for 20 minutes at room temperature

  • Rinse thoroughly in PBS or TBS (3 x 5 minutes)

• Blocking Protocol:

  • Block endogenous peroxidase with 3% H₂O₂ in methanol for 10 minutes

  • Block non-specific binding with 5% normal goat serum in PBS/0.1% Tween-20 for 1 hour

  • For tissues with high background, consider additional blocking with avidin/biotin blocking kit

• Antibody Incubation:

  • Apply optimized antibody dilution (typically 1:50-1:200 for IHC)

  • Incubate overnight at 4°C in a humidified chamber

  • Include positive control tissues (e.g., hair follicle-containing skin sections) and negative controls

This methodological procedure emphasizes the technical aspects of HOXC13 detection rather than commercial considerations, providing researchers with optimized protocols based on the molecular properties of HOX transcription factors and their nuclear localization.

What validation experiments should be performed to confirm specificity of HOXC13 antibodies?

A comprehensive validation strategy is essential to ensure the specificity and reliability of HOXC13 antibodies. The following methodological approach addresses this research question:

• Genetic Controls:

  • Knockout/Knockdown Verification: Test antibody on HOXC13 knockout or siRNA-knockdown samples to confirm absence of signal

  • Overexpression Systems: Evaluate antibody on cell lines with ectopic HOXC13 expression to verify increased signal

• Molecular Weight Verification:

  • Perform Western blot analysis on positive control samples (e.g., HeLa cells)

  • Confirm detection of a single band at the expected molecular weight

  • Compare with recombinant HOXC13 protein as a positive control

• Peptide Competition Assay:

  • Pre-incubate antibody with immunizing peptide or recombinant HOXC13

  • Apply to parallel tissue sections or Western blot lanes

  • Confirm signal elimination when antibody is neutralized by specific peptide

• Cross-Reactivity Assessment:

  • Test antibody against related HOX proteins (e.g., HOXB13, HOXA13)

  • Evaluate specificity across species if performing comparative studies

  • Document and quantify any observed cross-reactivity

• Reproducibility Testing:

  • Perform technical replicates across multiple experimental batches

  • Document lot-to-lot variation if using different antibody preparations

  • Establish standard positive controls for ongoing quality control

This validation framework provides researchers with a methodological approach to confirm antibody specificity before proceeding with critical experiments, ensuring scientific rigor and reproducibility in HOXC13 research.

How should researchers optimize Western blot protocols for detecting HOXC13 in different tissue types?

Optimizing Western blot protocols for HOXC13 detection requires methodological adjustments based on tissue-specific considerations. The following comprehensive approach addresses the technical challenges:

• Tissue-Specific Extraction Protocols:

  • Epithelial Tissues (primary HOXC13 expression sites):

    • Use RIPA buffer supplemented with 1% SDS

    • Include protease inhibitors, DNase I, and phosphatase inhibitors

    • Mechanical homogenization followed by sonication (3 x 10s pulses)

  • Nuclear Extraction (for transcription factor enrichment):

    • Implement fractionation protocol to isolate nuclear proteins

    • Use high-salt (>300mM NaCl) buffer for efficient extraction

    • Consider benzonase treatment to release DNA-bound proteins

• Sample Preparation Optimization:

  • Determine optimal protein loading (25-50μg per lane)

  • Denature samples at 95°C for 5 minutes in Laemmli buffer

  • Use freshly prepared DTT (50mM final concentration) in loading buffer

• Gel and Transfer Parameters:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Transfer to PVDF membrane at 100V for 60 minutes in 10% methanol transfer buffer

  • Verify transfer efficiency with reversible staining (Ponceau S)

• Antibody Incubation Protocol:

  • Block membranes with 3-5% nonfat dry milk in TBST

  • Optimize primary antibody dilution (1:500-1:2000)

  • Incubate overnight at 4°C with gentle agitation

  • Extend washing steps (5 x 5 minutes) to reduce background

• Detection Optimization:

  • For low abundance in certain tissues, use high-sensitivity ECL reagents

  • Consider longer exposure times (up to 90 seconds) for weaker signals

  • Use β-actin or GAPDH as loading controls for whole cell lysates

  • Use Lamin B1 as loading control for nuclear fractions

This methodological framework provides researchers with tissue-specific considerations for HOXC13 detection by Western blot, emphasizing technical optimization rather than commercial aspects of antibody usage.

What are common sources of false positives/negatives when using HOXC13 antibodies and how can they be addressed?

Understanding potential sources of false results is critical for accurate interpretation of HOXC13 antibody data. The following comprehensive analysis addresses common issues and their solutions:

Key methodological strategies to improve reliability include:

• Comprehensive Controls:

  • Positive tissue controls with known HOXC13 expression

  • Negative controls using isotype-matched immunoglobulins

  • Secondary-only controls to assess non-specific binding

• Technical Validation:

  • Confirm findings with alternative detection methods

  • Use multiple antibody clones targeting different epitopes

  • Correlate protein detection with mRNA expression data

This troubleshooting framework provides researchers with methodological approaches to identify and address common sources of error in HOXC13 antibody applications, ensuring greater reliability and reproducibility in experimental results.

How do researcher-generated HOXC13 antibodies compare with commercial antibodies in terms of specificity and applications?

The comparison between researcher-generated and commercial HOXC13 antibodies involves several methodological considerations that impact experimental outcomes:

• Epitope Selection and Coverage:

  • Researcher-Generated: Often target specific peptide sequences (e.g., amino acids 1-330 of human HOXC13) , allowing customization for particular applications

  • Commercial Antibodies: Typically utilize conserved regions to maximize cross-species reactivity and application breadth

  • Methodological Impact: Epitope selection influences detection of splice variants, posttranslational modifications, and protein-protein interactions

• Validation Depth:

  • Researcher-Generated: Validation often specific to research question, may have limited cross-application testing

  • Commercial Antibodies: Undergo standardized validation across multiple applications (WB, IHC, IF)

  • Methodological Recommendation: Implement independent validation regardless of antibody source, focusing on the specific experimental context

• Application-Specific Performance:

  • Western Blot: Both types can perform well; researcher antibodies may offer higher specificity for particular isoforms

  • Immunohistochemistry: Commercial antibodies often optimized for broader fixation conditions

  • ChIP Applications: Researcher antibodies designed specifically for immunoprecipitation may offer superior performance

• Reproducibility Considerations:

  • Researcher-Generated: Batch-to-batch variation can be significant; limited supply

  • Commercial Antibodies: Greater consistency between lots, but reformulations can occur

  • Methodological Solution: Maintain frozen aliquots of validated antibody lots; perform comparative testing between batches

• Recommended Validation Protocol:

  • Generate biochemical profiles comparing both antibody types on the same samples

  • Test reactivity against recombinant HOXC13 protein

  • Perform knockout/knockdown validation

  • Document specificity differences with Western blot and immunoprecipitation

This methodological analysis provides researchers with a framework for selecting appropriate antibodies based on their specific experimental needs rather than commercial considerations, emphasizing the scientific requirements for reliable HOXC13 detection.

What experimental approach is recommended for studying HOXC13 protein-protein interactions?

Investigating HOXC13 protein-protein interactions requires a systematic experimental approach tailored to transcription factor biology. The following comprehensive methodology is recommended:

• Co-Immunoprecipitation (Co-IP) Strategy:

  • Nuclear Extraction Protocol:

    • Implement specialized nuclear extraction using high-salt buffers (300-400mM NaCl)

    • Include nuclease treatment to release chromatin-bound complexes

    • Preserve protein-protein interactions with reversible crosslinkers (DSP)

  • Antibody Selection:

    • Use antibodies validated for immunoprecipitation applications

    • Employ multiple antibodies targeting different HOXC13 epitopes

    • Consider epitope-tagged HOXC13 expression systems for cleaner pulldowns

  • Controls and Validation:

    • IgG control for non-specific binding

    • Input control (10% of starting material)

    • Reverse immunoprecipitation to confirm interactions

• Proximity Ligation Assay (PLA) for In Situ Detection:

  • Implement dual-antibody PLA to visualize endogenous interactions

  • Optimize fixation to preserve nuclear architecture (2% PFA, 10 minutes)

  • Use HOXC13 antibody in combination with antibodies against suspected interaction partners

  • Quantify interaction signals using automated image analysis

• Mass Spectrometry-Based Interactome Analysis:

  • SILAC Approach: Label cells with heavy/light amino acids for quantitative comparison

  • Sample Preparation: Perform HOXC13 immunoprecipitation from nuclear extracts

  • Controls: Include matched IgG pulldowns and HOXC13-depleted samples

  • Data Analysis: Implement stringent filtering based on enrichment ratios and statistical significance

• Functional Validation of Interactions:

  • Reporter Assays: Test transcriptional effects of HOXC13 with interaction partners

  • Domain Mapping: Generate truncation mutants to identify interaction interfaces

  • ChIP-seq Analysis: Investigate co-occupancy at genomic loci

This methodological framework provides researchers with a comprehensive approach to investigating HOXC13 protein-protein interactions, emphasizing technical considerations specific to nuclear transcription factors rather than commercial aspects of antibody products.

How does HOXC13 expression compare with HOXB13 in cancer research applications?

The comparative analysis of HOXC13 and HOXB13 expression in cancer research reveals distinct tissue-specific patterns and methodological considerations for antibody-based detection:

• Tissue-Specific Expression Patterns:

  • HOXB13: Primarily associated with prostate tissue development and prostate cancer progression

  • HOXC13: More broadly expressed in epithelial tissues, with emerging evidence for roles in various epithelial malignancies

  • Methodological Implication: Tissue context is critical when selecting appropriate HOX antibodies for cancer research

• Expression in Cancer Progression:

  • HOXB13: Expression retained in most prostate cancers (including 84% of androgen receptor-negative and neuroendocrine prostate cancers)

  • HOXB13: Lower expression observed in higher-grade tumors, but no significant association with recurrence or disease-specific survival

  • HOXC13: Expression patterns in cancer progression less extensively characterized, requiring careful validation in specific tumor types

• Diagnostic Application Comparison:

  • HOXB13: Demonstrated 97% sensitivity and 99% specificity for prostatic origin in a cohort of 837 patients

  • HOXB13: Superior sensitivity compared to NKX3.1 for detecting advanced metastatic prostate cancers

  • HOXC13: Potential applications in diagnosing tumors of epithelial origin, particularly those derived from tissues with high normal HOXC13 expression

• Methodological Recommendations for Comparative Studies:

  • Use standardized IHC protocols with matched antibody dilutions

  • Implement quantitative scoring systems (H-score or Allred)

  • Include appropriate positive control tissues for each antibody

  • Consider dual staining approaches to evaluate co-expression patterns

This comparative analysis provides researchers with context-specific information for selecting appropriate HOX antibodies in cancer research applications, focusing on the biological significance and technical considerations rather than commercial aspects.

What methodological considerations are important when studying HOXC13 expression in developmental biology research?

Investigating HOXC13 expression in developmental contexts requires specialized methodological approaches to address the unique challenges of embryonic and developing tissues:

• Developmental Stage-Specific Fixation Protocols:

  • Embryonic Tissues: Shorter fixation times (4-6 hours) with 4% PFA

  • Fetal Tissues: Modified Davidson's fixative for improved epitope preservation

  • Postnatal Developing Tissues: Standard 10% neutral buffered formalin (24 hours)

  • Methodological Rationale: Developmental tissues often require gentler fixation to preserve antigenicity while maintaining morphology

• Temporal Expression Analysis Strategies:

  • Consecutive Developmental Timepoints: Process tissues from multiple timepoints under identical conditions

  • Paired Sample Analysis: When possible, assess multiple developmental stages on the same slide

  • Quantification Methods: Implement digital image analysis with consistent thresholding across developmental stages

  • Controls: Include adult tissues with known HOXC13 expression patterns

• Co-Expression Studies During Development:

  • Dual Immunofluorescence: HOXC13 with developmental markers (e.g., cytokeratins for epithelial differentiation)

  • Sequential Sections: For antibodies requiring incompatible detection methods

  • Combined in situ/IHC: RNA detection with protein localization for transcription/translation correlation

• Species-Specific Considerations:

  • Murine Development: Similar patterns to HOXB13 with expression increasing during later developmental stages

  • Human Development: Differences in timing and expression patterns require human-specific validation

  • Methodological Adaptation: Antibody selection must account for epitope conservation across species

• Technical Recommendations for Developmental Studies:

  • Optimize antigen retrieval specifically for developmental tissues

  • Consider whole-mount immunostaining for early embryonic stages

  • Use tyramide signal amplification for detecting low expression levels

  • Implement automated quantification to track expression changes over developmental time

This methodological framework provides researchers with specialized approaches for studying HOXC13 in developmental contexts, emphasizing technical considerations specific to developmental biology research rather than commercial aspects of antibody products.

How can researchers best integrate findings from HOXC13 and other HOX family member studies to advance understanding of developmental and disease processes?

Integrating findings across HOX family members requires systematic methodological approaches that leverage the strengths of various antibodies and detection techniques:

• Multi-Omics Integration Framework:

  • Transcriptomic Analysis: Compare expression patterns of HOXC13 with other HOX genes

  • Proteomic Profiling: Use validated antibodies to confirm protein-level correlations

  • Epigenomic Correlation: Integrate DNA methylation data, as methylation affects HOX gene expression

  • Methodological Approach: Implement matched sample designs across platforms for direct comparability

• Comparative Regulatory Network Analysis:

  • ChIP-seq Studies: Compare genomic binding sites of multiple HOX proteins

  • Gene Regulatory Networks: Construct networks based on shared and unique targets

  • Protein Interaction Maps: Identify common cofactors and unique interaction partners

  • Technical Recommendation: Ensure antibody specificity for each HOX protein to prevent cross-reactivity

• Evolutionary Conservation Analysis:

  • Cross-Species Expression: Compare developmental roles across vertebrate models

  • Functional Conservation: Assess conservation of binding sites and protein interactions

  • Methodological Consideration: Validate antibody cross-reactivity for each species studied

• Translational Research Applications:

  • Diagnostic Panels: Develop multi-HOX antibody panels for improved diagnostic accuracy

  • Prognostic Indicators: Evaluate combined HOX expression patterns for outcome prediction

  • Therapeutic Targeting: Identify shared vulnerabilities across HOX-dependent processes

  • Implementation Strategy: Standardize detection protocols to ensure comparable results